| Post |
| Pre |
| LA |
|---|
| 5.5 |
| 5 |
| ME 1 | ME 2 | ME 3 | ME 4 | ME 5 | ME 6 | ME 7 | ME 8 | ME 9 | ME 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | - | - | - | - | - | - | - | 3 |
| 1 | 1.5 | 1.5 | - | - | - | - | - | - | - | 4 |
| Post |
| Pre |
| LO 1 | LO 2 | LO 3 | LO 4 | LO 5A | LO 5B | LO 6 | Total |
|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - |
| AME |
|---|
| 17 |
| 37 |
| Post |
| Pre |
| LOP 1 | LOP 2 | LOP 3 | LOP 4 | Total |
|---|---|---|---|---|
| - | - | - | - | - |
| - | - | - | - | - |
| central brain |
|---|
| 1.5 |
| 9.5 |

| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| Optic-unspecified(L) | 317 | 76.0% | 0.90 | 592 | 75.1% |
| AME(L) | 68 | 16.3% | 1.12 | 148 | 18.8% |
| LA(L) | 22 | 5.3% | -0.14 | 20 | 2.5% |
| CentralBrain-unspecified | 3 | 0.7% | 2.66 | 19 | 2.4% |
| ME(L) | 7 | 1.7% | 0.36 | 9 | 1.1% |
| upstream partner | # | NT | conns HBeyelet | % In | CV |
|---|---|---|---|---|---|
| HBeyelet (L) | 4 | HA | 53.5 | 69.3% | 0.2 |
| OA-AL2i3 (L) | 2 | OA | 8 | 10.4% | 0.2 |
| aMe6c (L) | 2 | Glu | 5 | 6.5% | 0.6 |
| MeVPMe12 (R) | 2 | ACh | 3.8 | 4.9% | 0.2 |
| aMe6b (L) | 1 | ACh | 1.5 | 1.9% | 0.0 |
| aMe4 (L) | 4 | ACh | 1.2 | 1.6% | 0.3 |
| aMe12 (L) | 2 | ACh | 0.8 | 1.0% | 0.3 |
| aMe_TBD1 (L) | 1 | GABA | 0.5 | 0.6% | 0.0 |
| MeVCMe1 (R) | 1 | ACh | 0.5 | 0.6% | 0.0 |
| aMe1 (L) | 1 | GABA | 0.5 | 0.6% | 0.0 |
| MeVP1 (L) | 1 | ACh | 0.5 | 0.6% | 0.0 |
| MeLo1 (L) | 1 | ACh | 0.2 | 0.3% | 0.0 |
| MeVC22 (L) | 1 | Glu | 0.2 | 0.3% | 0.0 |
| MeVCMe1 (L) | 1 | ACh | 0.2 | 0.3% | 0.0 |
| aMe5 (L) | 1 | ACh | 0.2 | 0.3% | 0.0 |
| l-LNv (R) | 1 | unc | 0.2 | 0.3% | 0.0 |
| aMe2 (L) | 1 | Glu | 0.2 | 0.3% | 0.0 |
| downstream partner | # | NT | conns HBeyelet | % Out | CV |
|---|---|---|---|---|---|
| aMe6c (L) | 2 | Glu | 171.8 | 30.3% | 0.2 |
| aMe6b (L) | 1 | ACh | 87.5 | 15.4% | 0.0 |
| aMe3 (L) | 1 | Glu | 60.5 | 10.7% | 0.0 |
| aMe6a (L) | 1 | ACh | 58.5 | 10.3% | 0.0 |
| HBeyelet (L) | 4 | HA | 53.5 | 9.4% | 0.1 |
| aMe30 (L) | 2 | Glu | 19.8 | 3.5% | 0.1 |
| l-LNv (L) | 4 | unc | 19.5 | 3.4% | 0.5 |
| MeVP43 (L) | 1 | ACh | 12.8 | 2.2% | 0.0 |
| aMe1 (L) | 2 | GABA | 11.5 | 2.0% | 0.9 |
| aMe10 (L) | 1 | ACh | 9.8 | 1.7% | 0.0 |
| aMe5 (L) | 8 | ACh | 8.8 | 1.5% | 0.6 |
| aMe_unclear (L) | 1 | Glu | 8.2 | 1.5% | 0.0 |
| OA-AL2i3 (L) | 2 | OA | 6.2 | 1.1% | 0.4 |
| aMe4 (L) | 9 | ACh | 5.2 | 0.9% | 0.4 |
| s-LNv (L) | 3 | ACh | 4.5 | 0.8% | 0.5 |
| MeVC20 (L) | 2 | Glu | 4 | 0.7% | 0.4 |
| MeVPMe12 (R) | 2 | ACh | 2.8 | 0.5% | 0.5 |
| aMe2 (L) | 4 | Glu | 2.8 | 0.5% | 0.7 |
| Tm5c (L) | 1 | Glu | 2.5 | 0.4% | 0.0 |
| MeVP33 (L) | 1 | ACh | 2.2 | 0.4% | 0.0 |
| SLP250 (L) | 1 | Glu | 2 | 0.4% | 0.0 |
| MeLo7 (L) | 6 | ACh | 2 | 0.4% | 0.4 |
| LoVP54 (L) | 1 | ACh | 1.5 | 0.3% | 0.0 |
| Cm31a (L) | 1 | GABA | 1 | 0.2% | 0.0 |
| aMe12 (L) | 2 | ACh | 1 | 0.2% | 0.5 |
| Lat1 (L) | 2 | unc | 1 | 0.2% | 0.0 |
| Cm1 (L) | 2 | ACh | 1 | 0.2% | 0.0 |
| MeVP2 (L) | 1 | ACh | 0.5 | 0.1% | 0.0 |
| Lat3 (L) | 1 | unc | 0.5 | 0.1% | 0.0 |
| l-LNv (R) | 2 | unc | 0.5 | 0.1% | 0.0 |
| MeVP35 (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| T1 (L) | 1 | HA | 0.2 | 0.0% | 0.0 |
| Lat2 (L) | 1 | unc | 0.2 | 0.0% | 0.0 |
| MeVP1 (L) | 1 | ACh | 0.2 | 0.0% | 0.0 |
| MeVPMe6 (R) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| MeVP29 (L) | 1 | ACh | 0.2 | 0.0% | 0.0 |
| Cm11d (L) | 1 | ACh | 0.2 | 0.0% | 0.0 |
| MeVP51 (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| aMe17c (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| PLP080 (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| aMe26 (L) | 1 | ACh | 0.2 | 0.0% | 0.0 |
| LO_unclear (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| Cm17 (L) | 1 | GABA | 0.2 | 0.0% | 0.0 |
| MeVC22 (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| aMe_TBD1 (L) | 1 | GABA | 0.2 | 0.0% | 0.0 |
| aMe17e (L) | 1 | Glu | 0.2 | 0.0% | 0.0 |
| MeVPMe13 (R) | 1 | ACh | 0.2 | 0.0% | 0.0 |
| aMe17a (L) | 1 | unc | 0.2 | 0.0% | 0.0 |